 This study uses nanochemistry in micelles to produce a nanocarrier of erythropoietin, EPO, and traces the metabolizable process of the EPO carrier in vivo. The curative effects of the EPO nanocarriers for periventricular locomalacia, PVL, models are validated by analyzing pathology and praxeology of mice. The study demonstrates that EPO nanocarriers can ameliorate drug-induced liquefaction caused by hypoxia, effectively prolong the metabolic half-life and clearance time of EPO, and inhibit amino acid toxicity by protecting late oligodendrocyte mobilization from hypoxia. This article was authored by Ting Wang, Yan Hu, Long Zhang, and others.